Clinuvel Pharmaceuticals Management
Management criteria checks 3/4
Clinuvel Pharmaceuticals' CEO is Philippe Wolgen, appointed in Nov 2005, has a tenure of 18.42 years. total yearly compensation is A$6.39M, comprised of 24.9% salary and 75.1% bonuses, including company stock and options. directly owns 6.84% of the company’s shares, worth A$51.34M. The average tenure of the management team and the board of directors is 11.6 years and 7.8 years respectively.
Key information
Philippe Wolgen
Chief executive officer
AU$6.4m
Total compensation
| CEO salary percentage | 24.9% |
| CEO tenure | 18.4yrs |
| CEO ownership | 6.8% |
| Management average tenure | 11.6yrs |
| Board average tenure | 7.8yrs |
Recent management updates
Recent updates
If EPS Growth Is Important To You, Clinuvel Pharmaceuticals (ASX:CUV) Presents An Opportunity
Aug 11
Calculating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Jun 27Is Now The Time To Put Clinuvel Pharmaceuticals (ASX:CUV) On Your Watchlist?
May 09Estimating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Mar 24An Intrinsic Calculation For Clinuvel Pharmaceuticals Limited (ASX:CUV) Suggests It's 41% Undervalued
Nov 18Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now
Oct 20Is Clinuvel Pharmaceuticals Limited (ASX:CUV) Trading At A 21% Discount?
Jul 30Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Could Be 27% Below Their Intrinsic Value Estimate
Feb 27Does Clinuvel Pharmaceuticals (ASX:CUV) Deserve A Spot On Your Watchlist?
Dec 14This Is The Reason Why We Think Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Might Be Underpaid
Nov 03A Look At The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Sep 23Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today
Jul 23With EPS Growth And More, Clinuvel Pharmaceuticals (ASX:CUV) Is Interesting
Apr 10Have Insiders Sold Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Recently?
Mar 06Earnings Miss: Clinuvel Pharmaceuticals Limited Missed EPS By 41% And Analysts Are Revising Their Forecasts
Feb 27What Is The Ownership Structure Like For Clinuvel Pharmaceuticals Limited (ASX:CUV)?
Feb 20Clinuvel Pharmaceuticals (ASX:CUV) Shareholders Have Enjoyed A Whopping 648% Share Price Gain
Feb 01Estimating The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Jan 14We Wouldn't Rely On Clinuvel Pharmaceuticals's (ASX:CUV) Statutory Earnings As A Guide
Dec 28
Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Dec 10What You Need To Know About Clinuvel Pharmaceuticals Limited's (ASX:CUV) Investor Composition
Nov 21CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | AU$30m |
| Sep 30 2023 | n/a | n/a | AU$30m |
| Jun 30 2023 | AU$6m | AU$2m | AU$31m |
| Mar 31 2023 | n/a | n/a | AU$29m |
| Dec 31 2022 | n/a | n/a | AU$26m |
| Sep 30 2022 | n/a | n/a | AU$24m |
| Jun 30 2022 | AU$7m | AU$1m | AU$21m |
| Mar 31 2022 | n/a | n/a | AU$22m |
| Dec 31 2021 | n/a | n/a | AU$24m |
| Sep 30 2021 | n/a | n/a | AU$24m |
| Jun 30 2021 | AU$5m | AU$2m | AU$25m |
| Mar 31 2021 | n/a | n/a | AU$23m |
| Dec 31 2020 | n/a | n/a | AU$21m |
| Sep 30 2020 | n/a | n/a | AU$18m |
| Jun 30 2020 | AU$3m | AU$2m | AU$15m |
| Mar 31 2020 | n/a | n/a | AU$15m |
| Dec 31 2019 | n/a | n/a | AU$15m |
| Sep 30 2019 | n/a | n/a | AU$16m |
| Jun 30 2019 | AU$1m | AU$894k | AU$18m |
| Mar 31 2019 | n/a | n/a | AU$17m |
| Dec 31 2018 | n/a | n/a | AU$16m |
| Sep 30 2018 | n/a | n/a | AU$15m |
| Jun 30 2018 | AU$2m | AU$818k | AU$13m |
| Mar 31 2018 | n/a | n/a | AU$10m |
| Dec 31 2017 | n/a | n/a | AU$6m |
| Sep 30 2017 | n/a | n/a | AU$7m |
| Jun 30 2017 | AU$2m | AU$787k | AU$7m |
Compensation vs Market: Philippe's total compensation ($USD4.15M) is above average for companies of similar size in the Australian market ($USD785.78K).
Compensation vs Earnings: Philippe's compensation has been consistent with company performance over the past year.
CEO
Philippe Wolgen (60 yo)
18.4yrs
Tenure
AU$6,390,101
Compensation
Dr. Philippe Jacques Wolgen, MBA, M.D., has been the Chief Executive Officer and Managing Director of Clinuvel Pharmaceuticals Limited since November 28, 2005 to lead the corporate turnaround of the Group....
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Director | 18.4yrs | AU$6.39m | 6.84% A$ 51.3m | |
| CFO & Company Secretary | 18.3yrs | AU$3.09m | 0.36% A$ 2.7m | |
| Chief Scientific Officer | 11.6yrs | AU$636.85k | 0.31% A$ 2.4m | |
| Director of Global Operations | no data | no data | no data | |
| Head of Australian Operations & Investor Relations | no data | no data | no data | |
| Senior Vice President of Regulatory Affairs | less than a year | no data | no data | |
| Head of Quality & Drug Safety | less than a year | no data | no data |
11.6yrs
Average Tenure
Experienced Management: CUV's management team is seasoned and experienced (11.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Director | 18.5yrs | AU$6.39m | 6.84% A$ 51.3m | |
| Non-Executive Director | 17.2yrs | AU$85.00k | 0.23% A$ 1.7m | |
| Non-Executive Director | 4.6yrs | AU$75.00k | 0.00084% A$ 6.3k | |
| Non-Executive Chairman | 4.4yrs | AU$75.00k | 0.0063% A$ 47.2k | |
| Non-Executive Director | 9.3yrs | AU$115.00k | 3.48% A$ 26.1m | |
| Non-Executive Director | 6.3yrs | AU$75.00k | 0.011% A$ 82.5k |
7.8yrs
Average Tenure
Experienced Board: CUV's board of directors are considered experienced (7.8 years average tenure).